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We evaluated the effects of sequential therapy with caspofungin (CAS) or amphotericin B (AMB) followed
by posaconazole (POS) against Candida glabrata. The susceptibilities to POS of yeast cells pre-exposed to CAS
or AMB were identical to those of untreated cells as shown by standard Clinical and Laboratory Standards
Institute broth dilution, cell viability, and disk diffusion methods. We then investigated the activity of sequen-
tial regimens in an experimental model of disseminated candidiasis. CAS given at 1 mg/kg/day for 2 days
followed by POS at either 15 or 30 mg/kg/day significantly reduced the counts compared to the controls, but
this treatment was not superior to the use of CAS alone. Also, sequential regimens with AMB given at 1
mg/kg/day for 2 days followed by POS (AMB/POS) were effective at reducing the fungal burden against the
controls. In addition, AMB/POS with both doses of the triazole were significantly more effective than AMB
alone. Overall, our data showed that there is no therapeutic advantage in using CAS followed by POS, whereas
an induction therapy with AMB followed by a maintenance regimen with POS might be a suitable strategy in
managing C. glabrata infections.
Systemic fungal infections are a major cause of morbidity
and mortality in debilitated patients. The spectrum of invasive
fungal infections is changing, with an increased frequency of
infections due to non-Candida albicans spp. Candida glabrata
has recently emerged as the second most common cause of
invasive candidiasis (14, 15). Systemic infections due to C.
glabrata are characterized by a high mortality rate, and they are
difficult to treat due to a reduced susceptibility of this species
to azole drugs, especially to fluconazole (FLU) (14, 15). Accord-
ing to the published guidelines, amphotericin B (AMB) can be
used to treat infections due toC. glabrata, especially in profoundly
immunocompromised hosts (14). However, recent data suggest
that a growing proportion of C. glabrata isolates may be resistant
to AMB. This species appears to be susceptible to caspofungin
(CAS), making this agent a valuable alternative as first-line ther-
apy against this non-albicans species (10, 14).
Recently, posaconazole (POS) has been developed mainly to
combat the development of resistance to azoles in yeasts, in par-
ticular to FLU, and to expand the spectrum of susceptible patho-
gens (1, 3, 5–7, 16–21). Numerous in vitro studies demonstrated
that POS has a broad spectrum of activity against the majority of
yeasts, filamentous fungi, and azole-resistant Candida species (16,
18). Concurrent and sequential antifungal treatment has been
considered for invasive mycoses to improve the results of mono-
therapy. The new triazole, POS, which is available for oral ad-
ministration, is expected to be used in different sequences in the
course of systemic candidiasis. One possibility is to use CAS or
AMB followed by POS. Therefore, in the present study we inves-
tigated the effects of sequential therapy with CAS or AMB and
POS for the treatment of C. glabrata infections.
MATERIALS AND METHODS
Isolates. Four clinical isolates of C. glabrata (isolates 4198, 4205, 4293, and
4370) were used. The isolates were recovered from blood. Each strain repre-
sented a unique isolate from a patient. Yeast isolates were identified at the
species level by conventional morphological and biochemical methods and stored
at 70°C in 10% glycerol. Before the initiation of the study, yeast isolates were
subcultured on antimicrobial-agent-free medium to ensure viability and purity.
Candida parapsilosis ATCC 22019 was used as a quality control (12).
Drugs. POS (Schering Plough Research Institute, Kenilworth, N.J.) was pre-
pared with polyethylene glycol 200 (PEG-200; Janssen Chimica, Geel, Belgium)
for both in vitro and in vivo studies. CAS was used as a commercial preparation
(Cancidas; Merck Sharp & Dohme) for both in vitro and in vivo experiments. It
was dissolved according to the manufacturer’s instructions. AMB was used as
pure powder (Sigma) for in vitro studies and as a commercial preparation
(Fungizone; Bristol-Myers Squibb) for in vivo studies. It was dissolved in dim-
ethyl sulfoxide and in sterile water according to the manufacturer instructions for
in vitro and in vivo studies, respectively.
In vitro studies. (i) Broth dilution. Antifungal susceptibility testing was per-
formed by a broth microdilution method in accordance with the Clinical and
Laboratory Standards Institute (CLSI; formerly the National Committee for
Clinical Laboratory Standards) recommendations (12). The final concentrations
of all drugs ranged from 0.0078 to 8 g/ml. Plates were incubated at 35°C and
read at 24 and 48 h. Readings were performed spectrophotometrically (optical
density at 490 nm) with an automatic plate reader (ELx800; Biotek). POS and
CAS MICs were considered as the first concentration of the antifungal agent at
which the turbidity in the well was 50% less than that in the control well (12, 13).
AMB MIC was considered the first concentration of the antifungal agent at
which the turbidity in the well was 90% less than that in the control well (12).
Experiments were performed in quintuplicate.
(ii) Exposure to CAS or AMB. To study the effects of exposure to either CAS
or AMB on the susceptibility patterns of POS, yeast cells were grown overnight
in drug-free RPMI 1640 (Sigma) (unexposed cells) or in RPMI 1640 containing
CAS or AMB at either one-eighth or one-half the MIC (exposed cells). The cells
were then washed twice, counted, and diluted to obtain suitable inocula (0.5 
103 to 2.5  103 CFU/ml for broth dilution and 1  106 CFU/ml for halo assay)
for POS susceptibility testing. Experiments were performed in quintuplicate.
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(iii) CFU determination. Determination of the numbers of CFU per milliliter
was performed only with C. glabrata 4293. After MICs were read, 100-l samples
from the wells corresponding to either 2 or 16 times the POS MICs were
withdrawn and plated onto Sabouraud dextrose agar plates. Inoculated plates
were incubated at 35°C, and the percentage of viable cells at 48 h was calculated.
Experiments were performed in triplicate.
(iv) Halo assay. Drug-exposed and unexposed yeast cells of C. glabrata 4293
were plated onto Mueller-Hinton agar (Biogenetics srl) plates supplemented
with 0.5 g of methylene blue (4). Six-mm-diameter BBL disks (Becton Dickin-
son) were embedded with 20 l of POS at concentrations of 5 or 15 g. After the
disks had dried, they were placed onto inoculated agar plates. The plates were
incubated at 35°C, and inhibition zone diameters were measured at 24 and 48 h.
Experiments were performed in quintuplicate.
Animal experiments. CD1 male mice (Charles River, Calco, Lecco, Italy)
weighing 25 g were rendered neutropenic by intraperitoneal administration of
cyclophosphamide (200 mg/kg of body weight/day) on days 4, 1, and 4
postinfection. The animals were infected intravenously with C. glabrata 4293
given in a 0.2-ml volume. Two studies were performed: in study 1 the mice were
challenged with 2.44  108 CFU/mouse, and in study 2 the mice were challenged
with 1.04  108 CFU/mouse. Therapy was initiated 24 h postchallenge: POS was
administered at 0.2 ml orally by gavage once daily at doses of 15 mg/kg/day (study
1) and 30 mg/kg/day (study 2). Either CAS or AMB was given intraperitoneally
in 0.2 ml at a dose of 1 mg/kg/day in both studies. Drug efficacy was assessed by
determining the number of CFU per kidney pair. Briefly, the mice were sacri-
ficed, the kidneys were homogenized and diluted and undiluted aliquots, includ-
ing the entire organ, were grown on Sabouraud dextrose agar for colony count
determination. In both studies, nine groups of animals were considered: (i)
placebo treatment (P3; sterile saline solution) from day 1 to day 2 postinfection,
(ii) CAS from day 1 to day 2 (CAS), (iii) AMB from day 1 to day 2 (AMB), (iv)
placebo treatment from day 1 to day 6 (P7; sterile saline solution from day 1 to
day 2 and PEG-200 from day 3 to day 6), (v) P from day 1 to day 2 followed by
POS from day 3 to day 6 (P/POS), (vi) CAS from day 1 to day 2 followed by
P from day 3 to day 6 (CAS/P), (vii) CAS from day 1 to day 2 followed by POS
from day 3 to day 6 (CAS/POS), (viii) AMB from day 1 to day 2 followed by P
from day 3 to day 6 (AMB/P), and (ix) AMB from day 1 to day 2 followed by
POS from day 3 to day 6 (AMB/POS). Groups 1 to 3 were sacrificed on day 3
postinfection. Groups 4 to 9 were sacrificed on day 7 postinfection. There were
seven to eight animals in each group. Animal experiments were conducted with
the approval of University of Ancona Ethics Committee.
Statistical analysis. The in vitro susceptibility data were compared by using
the Student t test or the Mann-Whitney U test. A P value of 0.05 was consid-
ered statistically significant. The Mann-Whitney U test was also used to compare
tissue burden counts. Due to multiple comparisons, a P value of 0.016 was
considered statistically significant.
RESULTS
In vitro studies. (i) MICs. MIC data are shown in Table 1.
MICs for C. parapsilosis ATCC 22019 were within the expected
ranges (12).
According to FLU susceptibility definition, only isolate 4205
was susceptible to the triazole (median MIC of 1.0 g/ml).
Isolates 4370 and 4293 were susceptible to FLU in a dose-
dependent manner (susceptible dose dependent [SDD], me-
dian MICs of 16 and 32 g/ml, respectively), while isolate 4198
was resistant (median MIC of 64 g/ml).
The median POS MICs were 0.5, 0.03, 0.25, and 0.06
g/ml for isolates 4198, 4205, 4293, and 4370, respectively. The
median CAS MICs were 0.25, 0.25, 0.03, and 0.125 g/ml for
isolates 4198, 4205, 4293, and 4370, respectively. The median
AMB MICs for all isolates ranged from 0.5 to 1.0 g/ml.
AMB exposure of yeast cells to one-half of their respective
MICs did not have any significant effects on POS susceptibility.
In fact, POS MICs of exposed cells were identical or similar
(within one double dilution) to those reported for unexposed
cells. Similarly, POS MICs of yeasts cells exposed to CAS were
similar to those reported for unexposed cells (Table 1).
(ii) CFU determinations. Figure 1 shows the effects of POS
on the viability of yeast cells of C. glabrata 4293 grown over-
night in drug-free RPMI 1640 medium or medium containing
CAS or AMB at one-half MIC. The triazole exerted a dose-
dependent activity with percentages of viability ranging from
6.2 to 15.2 and from 0.01 to 0.06 for cells incubated at 2 and 16
times the POS MIC, respectively. In general, exposure to ei-
ther CAS or AMB did not show any significant variation in the
viability of yeast cells with respect to unexposed cells.
(iii) Halo assay. To further investigate the possible effects of
drug exposure on POS susceptibility, we compared the diam-
eters of growth inhibition of exposed and unexposed yeast cells
(Table 2). Although there was a tendency toward a slightly
reduction of diameters for cells exposed to both CAS and
AMB with respect to unexposed cells, the difference was not
statistically significant.
In vivo studies. To investigate this interaction in vivo, CD1
mice were infected intravenously with C. glabrata 4293 and
treated with several therapeutic regimens, including schemes
of sequential therapy. Figure 2A and B show the results of
studies 1 and 2, respectively. In both studies, nine groups of
animals were considered. Neither CAS nor AMB were effec-
tive at reducing the fungal burden on day 3 postinfection in
both studies. There was an increase of kidney burdens from
day 3 (P3) to day 7 (P7) postinfection in both studies, suggest-
ing a progression of the infection in the untreated animals.
TABLE 1. In vitro susceptibilities of yeast isolates used in this study to FLU, AMB, CAS, and POS
Isolatesa
Median MIC in g/ml (range) for ofb:
FLU AMB CAS POSc
C. parapsilosis ATCC 22019 4.0 (2.0–4.0) 1.0 (1.0) 0.25 (0.25) 0.03 (0.03)
C. glabrata 4198 64 (64) 0.5 (0.5–1.0) 0.25 (0.06–0.25) 0.5 (0.5–2.0), 0.5 (0.5–1.0)*, 1.0 (0.5–2.0)†
C. glabrata 4205 1.0 (1.0–4.0) 0.5 (0.25–0.5) 0.25 (0.25) 0.03 (0.03), 0.03 (0.03–0.06)*,
0.06 (0.03–0.06)†
C. glabrata 4293 32 (32–64) 0.5 (0.5) 0.03 (0.03–0.06) 0.25 (0.125–0.25), 0.25 (0.125–0.25)*,
0.125 (0.125–0.25)†
C. glabrata 4370 16 (8.0–16) 1.0 (1.0–2.0) 0.125 (0.125) 0.06 (0.06–0.125), 0.06 (0.06–0.125)*,
0.125 (0.06–0.25)†
a Each isolate was tested five times.
b Readings were performed spectrophotometrically at either 24 or 48 h with an automatic plate reader (ELx800; Biotek) set at 490 nm. The results were similar
(within one double dilution). MICs refer to 48-h readings for POS, FLU, and AMB and to 24-h readings for CAS.
c *, Susceptibility to POS after overnight exposure of yeast isolates to AMB at their respective one-half MIC; †, susceptibility to POS after overnight exposure of yeast
isolates to CAS at their respective one-half MIC.
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Among the groups sacrificed on day 7, both doses of POS
initiated on day 3 postinfection (P/POS) showed a reduction of
CFU with respect to their controls, but the difference was not
statistically significant. On the other hand, counts for the kid-
neys of mice treated with CAS for 2 days and sacrificed on day
7 postinfection (CAS/P) were significantly reduced compared
to those of untreated controls (P  0.0002 and 0.0003 in
studies 1 and 2, respectively). Similarly, sequential therapy with
CAS followed by POS at either 15 or 30 mg/kg/day (CAS/POS)
significantly reduced the counts compared to the controls (P 
0.0003). However, neither sequential therapy was more effec-
tive than CAS/P.
AMB/P and AMB/POS were all effective at reducing the
fungal burden in the controls (P values ranging from 0.0003 to
0.013). In addition, sequential therapies with both doses of the
triazole were significantly more effective than AMB/P (P 
0.006 and 0.0006 in studies 1 and 2, respectively).
DISCUSSION
In this study, we evaluated the effects of sequential therapies
with AMB or CAS followed by POS for treatment of C.
glabrata infections.
Our in vitro data indicate that pre-exposure of C. glabrata to
CAS or AMB did not alter the fungal susceptibility to POS.
This phenomenon was seen with three different assays. First,
CAS or AMB pre-exposure of four C. glabrata isolates to
one-half of their respective MICs did not have any significant
effect on the POS susceptibility investigated by the CLSI broth
dilution method. Similarly, pre-exposure to either CAS or
AMB did not cause any significant variations in the viability of
yeast cells with respect to the unexposed cells. Finally, POS
disk diffusion diameters did not vary significantly when the four
C. glabrata isolates were pre-exposed to CAS or AMB at one-
half or one-eighth their respective MICs. Previous literature
data on sequential therapy of AMB and triazoles have dem-
onstrated that the order of drug administration can play a
critical role (11). Although the majority of in vitro data are
limited for C. albicans, the sequential exposure to FLU fol-
lowed by AMB caused the fungus to be transiently resistant to
the polyene. It has been proposed that pre-exposure of the
fungus to azoles depletes ergosterol, which is the prime target
for AMB action (11). Consequently, added AMB will not have
the cellular target necessary for its activity, resulting in antag-
onistic interaction. On the contrary, it has been hypothesized
that AMB, by binding to fungal membrane sterols and creating
a pore, provides greater access to azoles into the cytoplasm,
leading to increased inhibition of ergosterol synthesis. Studies
on sequential therapy of CAS followed by triazoles against
Candida spp. are limited (2). Our previous in vitro data indi-
cate that exposure to CAS does not alter the initial suscepti-
bility to FLC in C. albicans (2).
The present in vitro data correlate with the outcome of our
FIG. 1. Effects of posaconazole on the viability of C. glabrata 4293 grown overnight in drug-free RPMI 1640 medium () or medium containing
caspofungin (u) or amphotericin B (f) at one-half the MIC (0.015 and 0.25 g/ml, respectively). Experiments were performed with an initial
inoculum that ranged from 0.5  103 to 2.5  103 CFU/ml. POS MICs were determined according to the CLSI method against either exposed or
unexposed cells. The number of CFU per milliliter was determined by plating the wells containing POS at 2 and 16 the MIC (0.5 and 4.0 g/ml,
respectively). The data are averages of the percentage of viable cells at 48 h with respect to the controls, and error bars denote the standard
deviations.
TABLE 2. In vitro activity of POS against C. glabrata 4293 by the
halo assaya
Treatmentb
Mean halo diam (mm) 
SD of POS tested at:
5 g/disk 15 g/disk
Unexposed cells 29.0 2.5 30.0  1.9
Exposed to CAS at one-half the MIC 26.8 0.4 29.0  1.2
Exposed to CAS at one-eighth the MIC 28.0 1.0 29.6  0.5
Exposed to AMB at one-half the MIC 28.4 1.7 29.8  0.4
Exposed to AMB at one-half the MIC 27.0 0.7 30.0  0.0
a C. glabrata 4293 was tested in five independent experiments. Readings were
performed at either 24 or 48 h. The results were identical, and 24-h readings are
shown in the table.
b C. glabrata 4293 was grown overnight in drug-free RPMI 1640 medium
(unexposed cells) or medium containing CAS or AMB at one-half the MIC
(0.015 and 0.25 mg/ml, respectively) or one-eighth the MIC (0.00375 and 0.0625
mg/ml, respectively).
VOL. 52, 2008 THERAPY WITH POSACONAZOLE VERSUS C. GLABRATA 515
 by on M











in vivo murine model of systemic candidiasis. Actually, the
switch from CAS or AMB to POS did not yield an antagonistic
effect.
We found that sequential therapy CAS/POS was as effective
as CAS followed by placebo (CAS/P). This result suggests that
there is no therapeutic advantage in using the sequential ther-
apy CAS followed by POS, at least with the doses and regimen
schemes investigated here. It is important to note that CAS
given for 2 days did not yield a regrowth in fungal burden, as
shown by a similar CFU level in the kidneys of mice sacrificed
on days 3 and 7 postinfection. Our results can be explained by
the findings of Louie et al., who investigated the pharmacody-
namic parameters linked with CAS efficacy in a murine model
of systemic candidiasis caused by C. albicans (9). These authors
demonstrated that therapeutic concentrations of CAS persist
at the site of infection in kidney tissue well after serum con-
centrations fall below the MIC, underscoring the primacy of
CAS levels in tissues in determining treatment outcome (9).
In contrast to what we observed with CAS/POS, the sequen-
tial scheme of AMB/POS proved more effective than the poly-
ene followed by placebo. Interestingly, this effect was seen at
both doses of POS. Also, we observed that AMB given for 2
days yielded a fungal regrowth on day 7 postinfection, as shown
by a significant increase in CFU counts between the AMB and
AMB/P groups. Recently, Hope et al. applied a mathematical
model on the time course of C. albicans kidney burden in
neutropenic mice treated with AMB (8). These researchers
observed a net growth of C. albicans after the administration of
0.63 mg of AMB/kg, while a dose of 5 mg/kg was required to
overcome progressive growth of C. albicans and produce a
FIG. 2. Tissue burden of kidneys of CD1 mice infected intravenously with C. glabrata 4239 and treated with P (sterile saline solution) from day
1 to day 2 postinfection (P3), CAS from day 1 to day 2 (CAS), AMB from day 1 to day 2 (AMB), P from day 1 to day 6 (P7; sterile saline solution
from day 1 to day 2 and PEG-200 from day 3 to day 6), P (sterile saline solution) from day 1 to day 2 followed by POS from day 3 to day 6 (P/POS),
CAS from day 1 to day 2 followed by P (PEG-200) from day 3 to day 6 (CAS/P), CAS from day 1 to day 2 followed by POS from day 3 to day
6 (CAS/POS), AMB from day 1 to day 2 followed by P (PEG-200) from day 3 to day 6 (AMB/P), or AMB from day 1 to day 2 followed by POS
from day 3 to day 6 (AMB/POS). The first three groups were sacrificed on day 3 postinfection. The last six groups were sacrificed on day 7
postinfection. In study 1, the animals were infected with 1.04  108 CFU/mouse and POS was administered at 15 mg/kg/day (A), while in study
2 the animals were challenged with 1.04 108 CFU/mouse and POS was administered at 30 mg/kg/day (B). The bars represent the medians. There
were seven to eight animals in each group.
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fungal density that was comparable to that observed at the time
of the initiation of therapy (8). Although we utilized a dose of
AMB at 1 mg/kg/day for 2 days and a different species of
Candida, our results are in agreement with their findings.
To our knowledge, this is the first study in which the efficacy
of POS against C. glabrata was investigated after a short expo-
sure to CAS or AMB. Overall, our data showed that there is no
therapeutic advantage in using CAS followed by POS, al-
though they seem to indicate that an induction therapy with
AMB followed by a maintenance regimen with POS might be
a suitable strategy in managing C. glabrata infections. An im-
portant point of this approach is the possibility to switch from
an intravenous to an oral therapy with both patient and cost
advantages.
Additional studies are warranted to further characterize the
potential benefits of sequential therapy with AMB and POS
against C. glabrata.
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